Human epidermal growth factor receptor 2-positive advanced breast cancer treated with Inetetamab:report of a case and review of literature
This study explored the effectiveness of combining Inetetamab with other targeted drugs in treating a case of Hu-man epidermal growth factor receptor 2(HER2)-positive recurrent metastatic breast cancer through retrospective analysis.The patient was a 59-year-old woman who received Trastuzumab during the neoadjuvant treatment period,and was diag-nosed with breast cancer with cervical lymph node metastasis and bone metastasis in December 2020.In the late first-line treatment,the patient received a regimen of albumin-bound paclitaxel combined with Inetetamab and Pertuzumab,achieving a nearly 15-month progression-free survival(PFS).In the late second-line treatment,a regimen of Pyrotinib combined with Capecitabine was used,with PFS exceeding 20 months and good tolerability.This treatment regimen brought good survival benefits to patients with HER2-positive breast cancer who relapsed after Trastuzumab treatment,and relevant literature re-views also supported the conclusion of this study.In summary,this study provides clinicians with new treatment strategies and methods that can help improve the treatment effect and quality of life of patients with HER2-positive breast cancer.However,more clinical trials are still needed to further verify the effectiveness and safety of this treatment regimen.
Human epidermal growth factor receptor 2 positive breast cancerInetetamabPyrotinibProgressive free survival
万方数据
维普
